Infection-induced inflammation and related muscle weakness Not Applicable
Conditions
Interventions
10 mg piroxicam daily versus placebo in addition to standard care including antibiotics
Sponsors
Brussels University Hospital (Belgium) (Universitair Ziekenhuis Brussel)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients hospitalised in an acute geriatric ward 2. Age > 70 years 3. Inflammation, not due to surgery or burns, and documented by an increase of serum concentration of C-reactive protein (CRP) (> 10 mg/L) and/or fibrinogen (>400 mg/dL) 4. Informed consent
Exclusion criteria
Exclusion criteria: 1. General condition, dementia or confusion, not allowing the testing 2. Patients in (pre) terminal phase 3. Use of corticosteroids or non -steroidal anti-inflammatory drugs (NSAIDs) in the past 7 days; the use of inhalation corticosteroids, of low dose aspirin (as anti-aggregating medication) or of paracetamol is allowed 4. Contra-indication for the use of cyclo-oxygenase (COX)-2 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Skeletal muscle mass (total body potassium) evaluated at baseline & weekly thereafter maximum two times 2. Muscle performance (grip strength, fatigue resistance and Elderly Mobility Scale (EMS) score evaluated at baseline & weekly thereafter with a maximum of three weeks 3. Inflammation (levels of cytokines and heat shock proteins) evaluated at baseline, daily during the first 3 days and weekly after baseline with a maximum of three weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical evolution evaluated at discharge 2. Length of stay 3. Tolerance and adverse events evaluated daily throughout hospitalisation | — |
Countries
Belgium
Outcome results
None listed